Skip to main content
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Mov Disord. 2023 Dec 18;39(2):428–432. doi: 10.1002/mds.29685

Table 2.

Summary of TEAEs (Safety Analysis Set)

Patients, n (%) Overall
N=419

≥1 TEAE 221 (52.7)
≥1 treatment-related TEAE 66 (15.8)
≥1 serious TEAE 42 (10.0)
TEAE leading to study drug discontinuation 25 (6.0)
TEAE leading to death 6 (1.4)
TEAEs reported in ≥2% of patients
 Dyskinesia 21 (5.0)
 Fall 21 (5.0)
 Urinary tract infection 21 (5.0)
 Back pain 15 (3.6)
 Constipation 11 (2.6)
 COVID-19 10 (2.4)

TEAE, treatment-emergent adverse event.